title: Capacitative Ca2+ entry is involved in cAMP synthesis in mouse parotid acini.
abstract: Muscarinic receptor interaction leading to augmentation of isoproterenol-stimulated cAMP accumulation in mouse parotid acini involves Ca2+ (28). The effectiveness of capacitative Ca2+ entry and intracellular Ca2+ release on this response was determined in time course studies by using three independent tools to manipulate the free intracellular Ca2+ concentration: the muscarinic agonist carbachol, thapsigargin, and ionomycin. Time course studies revealed that Ca2+ release from intracellular stores by carbachol produced an early rapid increase (0.25-0.5 min) in stimulated cAMP levels, whereas capacitative Ca2+ entry resulted in a sustained increase in stimulated cAMP levels that was blocked by La3+. Capacitative Ca2+ entry, alone, was involved in thapsigargin and ionomycin augmentation of stimulated cAMP accumulation. The inability of phosphodiesterase inhibitors, 3-isobutyl-1-methylxanthine and milrinone, to prevent agonist augmentation of cAMP levels, as well as the finding that the type VIII adenylyl cyclase (ACVIII) is expressed in parotid acini, suggests that capacitative Ca2+ entry augments stimulated cAMP accumulation, at least in part, via activation of this adenylyl cyclase isoenzyme.
authors.affiliation: Department of Oral Biology, University of Washington, Seattle 98195, USA.
authors.forename: E L
authors.initials: EL
authors.lastname: Watson
authors.forename: Z
authors.initials: Z
authors.lastname: Wu
authors.forename: K L
authors.initials: KL
authors.lastname: Jacobson
authors.forename: D R
authors.initials: DR
authors.lastname: Storm
authors.forename: J C
authors.initials: JC
authors.lastname: Singh
authors.forename: S M
authors.initials: SM
authors.lastname: Ott
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D015220:Calcium Channels / Q000378:metabolism*; D002217:Carbachol / Q000494:pharmacology; D002451:Cell Compartmentation; D000242:Cyclic AMP / Q000096:biosynthesis*; D006152:Cyclic GMP / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066298:In Vitro Techniques; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D007527:Isoenzymes / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D007811:Lanthanum / Q000378:metabolism; D051379:Mice; D018721:Muscarinic Agonists / Q000494:pharmacology; D010306:Parotid Gland / Q000187:drug effects / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D019284:Thapsigargin / Q000494:pharmacology
chemical_list: D000318:Adrenergic beta-Agonists; D015220:Calcium Channels; D004791:Enzyme Inhibitors; D007476:Ionophores; D007527:Isoenzymes; D018721:Muscarinic Agonists; D010726:Phosphodiesterase Inhibitors; D015759:Ionomycin; D019284:Thapsigargin; D007811:Lanthanum; D002217:Carbachol; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D006152:Cyclic GMP; D007545:Isoproterenol; D002118:Calcium; D015056:1-Methyl-3-isobutylxanthine